Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. Issue 4 (October 2016)

• Record Type: Journal Article
• Authors: McNaughton, Amanda; Blackmore, Timothy; McNaughton, Harry
• Is Part Of: European respiratory journal. Volume 48:Issue 4(2016)
• Page Start: 1256
• Page End: 1259
• Publication Date: 2016-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00876-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Diel and co-workers [1, 2] have reported the estimated cost of treating tuberculosis (TB) and multidrug-resistant (MDR)-TB in Germany and the European Union, which, along with estimated and modelling cost data from the USA, Asia and South Africa [3, 4], confirm the huge economic burden to range between 40 and 200 times higher than treating fully sensitive TB cases. We describe the full costs of treatment of a person who was treated in 2014–2015 in Wellington, New Zealand. He had MDR-TB plus ofloxacin resistance but marginal moxifloxacin susceptibility ( i.e. MDR/pre-extensively drug-resistant (XDR)-TB). This case highlights the key drivers of cost in a high-income country. € 200 000: the full cost of treating a single MDR/pre-XDR-TB patient in New Zealand http://ow.ly/NkGT301B5KN